CD4 and breast cancer: However, B cells remain significantly lower after 9 months, and memory CD4+ T cells exhibit an abnormal bias toward inflammatory effectors that persists for years, albeit in cohorts of breast cancer patients with mixed or unknown molecular subtypes63,64.